Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

13000 reported adverse events

Drugs of this class: GANCICLOVIR VALGANCICLOVIR

These side effects are most commonly reported by patients taking drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class:

# Side effect Count
0 CYTOMEGALOVIRUS INFECTION 1443
1 OFF LABEL USE 1304
2 DRUG INEFFECTIVE 957
3 PYREXIA 891
4 DIARRHOEA 693
5 NEUTROPENIA 676
6 LEUKOPENIA 637
7 DRUG RESISTANCE 598
8 PRODUCT USE IN UNAPPROVED INDICATION 588
9 CYTOMEGALOVIRUS VIRAEMIA 585
See all common reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

Drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CYTOMEGALOVIRUS SYNDROME 77 0.6210
1 CYTOMEGALOVIRUS NEPHRITIS 20 0.4545
2 SMOOTH MUSCLE CELL NEOPLASM 89 0.4279
3 ENCEPHALITIS CYTOMEGALOVIRUS 98 0.4033
4 OESOPHAGOPLEURAL FISTULA 11 0.3929
5 SCOPULARIOPSIS INFECTION 12 0.3750
6 PERICARDITIS FUNGAL 15 0.3659
7 CYTOMEGALOVIRUS GASTROINTESTINAL INFECTION 67 0.3300
8 GRANULOMATOUS ROSACEA 12 0.2857
9 FLAVOBACTERIUM INFECTION 9 0.2812
See all enriched reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]